Bausch Health In-Licenses Clearside’s Xipere (triamcinolone acetonide suprachoroidal injectable suspension) For Macular Edema Associated with Uveitis

 Bausch Health In-Licenses Clearside’s Xipere (triamcinolone acetonide suprachoroidal injectable suspension) For Macular Edema Associated with Uveitis

Bausch Health In-Licenses Clearside’s Xipere (triamcinolone acetonide suprachoroidal injectable suspension) For Macular Edema Associated with Uveitis

Shots:

  • Clearside to receive ~$20M prior to launch including an up front and is eligible to receive commercial & regulatory milestones on approval of Xipere for an additional indication and royalties on sales in the licensed territories
  • Bausch Health to get an exclusive license to develop & commercialize Xipere for macular edema associated with uveitis and can pursue its development & commercialization for additional ophthalmic indications in the US and Canada. Additionally, Bausch has the right to develop and commercialize Clearside’s SCS microinjector in combination with corticosteroids and NSAIDs in the US & Canada
  • Xipere (CLS-TA) is a suspension of the corticosteroid triamcinolone acetonide formulated for suprachoroidal administration via Clearside’s SCS microinjector with its expected resubmission of NDA to the US FDA in Q1’20

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Canada

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post